{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T22:10:08Z","timestamp":1750371008791,"version":"3.41.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Colombiana de Psiquiatr\u00eda"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.rcp.2017.05.010","type":"journal-article","created":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T07:00:34Z","timestamp":1498028434000},"page":"59-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S1","title":["Neuropsiquiatr\u00eda de los trastornos del movimiento"],"prefix":"10.1016","volume":"46","author":[{"given":"Juan Manuel","family":"Orjuela-Rojas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo Adolfo","family":"Barrios Vincos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melisa Alejandra","family":"Mart\u00ednez Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rcp.2017.05.010_bib0390","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1146\/annurev-physiol-021115-105355","article-title":"Cortico-basal ganglia circuit function in psychiatric disease","volume":"78","author":"Gunaydin","year":"2016","journal-title":"Ann Rev Physiol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0395","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00004691-200401000-00007","article-title":"Deep brain stimulation for psychiatric disorders","volume":"21","author":"Kopell","year":"2004","journal-title":"J Clin Neurophysiol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0400","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/2015.3.FOCUS1546","article-title":"Deep brain stimulation for psychiatric disorders: where we are now","volume":"38","author":"Cleary","year":"2015","journal-title":"Neurosurg Focus."},{"key":"10.1016\/j.rcp.2017.05.010_bib0405","unstructured":"Purves D. Neuroscience. 5.a ed. Boston: Sinauer; 2012."},{"key":"10.1016\/j.rcp.2017.05.010_bib0410","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/jnnp.72.1.12","article-title":"Neuropsychiatry of the basal ganglia","volume":"72","author":"Ring","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.rcp.2017.05.010_bib0415","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1749-6632.1999.tb09280.x","article-title":"Associative processes in addiction and reward The role of amygdala-ventral striatal subsystems","volume":"877","author":"Everitt","year":"1999","journal-title":"Ann N Y Acad Sci."},{"year":"2010","series-title":"Neuropsychology of movement disorders and motor neuron disease","key":"10.1016\/j.rcp.2017.05.010_bib0420"},{"key":"10.1016\/j.rcp.2017.05.010_bib0425","doi-asserted-by":"crossref","first-page":"758","DOI":"10.33588\/rn.3708.2003010","article-title":"Caracter\u00edsticas cl\u00ednicas y neuropsicol\u00f3gicas de la enfermedad de Huntington: una revisi\u00f3n","volume":"37","author":"Arango-Lasprilla","year":"2003","journal-title":"Rev Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0430","doi-asserted-by":"crossref","first-page":"14","DOI":"10.33588\/rn.6101.2015049","article-title":"Subtipos de deterioro cognitivo leve en la enfermedad de Parkinson y factores predictores de conversi\u00f3n a demencia","volume":"61","author":"Toribio-D\u00edaz","year":"2015","journal-title":"Rev Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0435","first-page":"1","article-title":"Aspecto neuropsicol\u00f3gicos de los trastornos del movimiento","author":"Barrera","year":"2009","journal-title":"Rev Psicol Uni Antioquia."},{"key":"10.1016\/j.rcp.2017.05.010_bib0440","doi-asserted-by":"crossref","first-page":"788","DOI":"10.33588\/rn.3008.99652","article-title":"Caracter\u00edsticas neuropsicol\u00f3gicas de la enfermedad de Parkinson","volume":"30","author":"Ostrosky-Sol\u00eds","year":"2000","journal-title":"Rev Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0445","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1177\/0269881114548437","article-title":"Perceptual decision-making in patients with Parkinson's disease","volume":"28","author":"Djamshidian","year":"2014","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0450","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archneur.60.3.387","article-title":"Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study","volume":"60","author":"Aarsland","year":"2003","journal-title":"Arch Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0455","first-page":"CD006504","article-title":"Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease","volume":"3","author":"Rolinski","year":"2012","journal-title":"Cochrane Database System Rev."},{"key":"10.1016\/j.rcp.2017.05.010_bib0460","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rcp.2017.05.010_bib0465","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/jnnp.72.6.708","article-title":"Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study","volume":"72","author":"Aarsland","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.rcp.2017.05.010_bib0470","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/jnnp.2004.050682","article-title":"Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study","volume":"76","author":"Ravina","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.rcp.2017.05.010_bib0475","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","article-title":"Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis","volume":"86","author":"Wang","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.rcp.2017.05.010_bib0480","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson's disease","volume":"23","author":"Reijnders","year":"2008","journal-title":"Mov Disord."},{"key":"10.1016\/j.rcp.2017.05.010_bib0485","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.parkreldis.2010.06.014","article-title":"Occurrence of depression and anxiety prior to Parkinson's disease","volume":"16","author":"Jacob","year":"2010","journal-title":"Parkinsonism Relat Disord."},{"key":"10.1016\/j.rcp.2017.05.010_bib0490","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrneurol.2011.189","article-title":"Depression in Parkinson disease\u2014epidemiology, mechanisms and management","volume":"8","author":"Aarsland","year":"2011","journal-title":"Nat Rev Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0495","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ana.410280111","article-title":"Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease","volume":"28","author":"Mayberg","year":"1990","journal-title":"Ann Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0500","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2377-10-49","article-title":"Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Skapinakis","year":"2010","journal-title":"BMC Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0505","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/01.wnl.0000215428.46057.3d","article-title":"Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Miyasaki","year":"2006","journal-title":"Neurology."},{"key":"10.1016\/j.rcp.2017.05.010_bib0510","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology."},{"key":"10.1016\/j.rcp.2017.05.010_bib0515","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.0b013e3181ebdd79","article-title":"Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease","volume":"75","author":"Weintraub","year":"2010","journal-title":"Neurology."},{"key":"10.1016\/j.rcp.2017.05.010_bib0520","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.mehy.2010.07.024","article-title":"Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments","volume":"75","author":"Raskin","year":"2010","journal-title":"Med Hypotheses."},{"key":"10.1016\/j.rcp.2017.05.010_bib0525","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurology."},{"key":"10.1016\/j.rcp.2017.05.010_bib0530","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0006-3223(99)00243-7","article-title":"A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry."},{"key":"10.1016\/j.rcp.2017.05.010_bib0535","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/mds.870060405","article-title":"Electroconvulsive therapy in Parkinson's disease and other movement disorders","volume":"6","author":"Faber","year":"1991","journal-title":"Mov Disord."},{"key":"10.1016\/j.rcp.2017.05.010_bib0540","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group","volume":"22","author":"Ravina","year":"2007","journal-title":"Mov Disord."},{"key":"10.1016\/j.rcp.2017.05.010_bib0545","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","article-title":"The psychosis spectrum in Parkinson disease","volume":"13","author":"Ffytche","year":"2017","journal-title":"Nat Rev Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0550","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/jnnp.2010.234799","article-title":"Feeling of presence in Parkinson's disease","volume":"82","author":"Fenelon","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.rcp.2017.05.010_bib0555","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.26432","article-title":"Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase","volume":"31","author":"Pagonabarraga","year":"2016","journal-title":"Mov Disord."},{"key":"10.1016\/j.rcp.2017.05.010_bib0560","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","article-title":"A 12-year population-based study of psychosis in Parkinson disease","volume":"67","author":"Forsaa","year":"2010","journal-title":"Arch Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0565","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/brain\/123.10.2055","article-title":"Visual hallucinatory syndromes and the anatomy of the visual brain","volume":"123","author":"Santhouse","year":"2000","journal-title":"Brain."},{"key":"10.1016\/j.rcp.2017.05.010_bib0570","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/WNL.50.2.515","article-title":"Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations","volume":"50","author":"Goetz","year":"1998","journal-title":"Neurology."},{"key":"10.1016\/j.rcp.2017.05.010_bib0575","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1212\/WNL.40.5.832","article-title":"Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis","volume":"40","author":"Wolters","year":"1990","journal-title":"Neurology."},{"key":"10.1016\/j.rcp.2017.05.010_bib0580","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.rcp.2017.05.010_bib0585","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet."},{"issue":"Suppl 3","key":"10.1016\/j.rcp.2017.05.010_bib0590","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1002\/mds.23884","article-title":"The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease","volume":"26","author":"Seppi","year":"2011","journal-title":"Mov Disord."},{"issue":"Suppl 1","key":"10.1016\/j.rcp.2017.05.010_bib0595","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S1353-8020(11)70026-8","article-title":"Impulse control disorders in Parkinson's disease","volume":"18","author":"Vilas","year":"2012","journal-title":"Parkinsonism Rel Disord."},{"key":"10.1016\/j.rcp.2017.05.010_bib0600","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1212\/01.wnl.0000238503.20816.13","article-title":"Prevalence of repetitive and reward-seeking behaviors in Parkinson disease","volume":"67","author":"Voon","year":"2006","journal-title":"Neurology."},{"issue":"Suppl 4","key":"10.1016\/j.rcp.2017.05.010_bib0605","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S1353-8020(09)70847-8","article-title":"Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management","volume":"15","author":"Ceravolo","year":"2009","journal-title":"Parkinsonism Rel Disord."},{"key":"10.1016\/j.rcp.2017.05.010_bib0610","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/CPJ.0b013e318278be9b","article-title":"Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease","volume":"2","author":"Weiss","year":"2012","journal-title":"Neurol Clin Pract."},{"key":"10.1016\/j.rcp.2017.05.010_bib0615","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1345\/aph.1A412","article-title":"Possible zoophilia associated with dopaminergic therapy in Parkinson disease","volume":"36","author":"Jimenez-Jimenez","year":"2002","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.rcp.2017.05.010_bib0620","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1017\/S1092852900013778","article-title":"Impulse-control disorders in Parkinson's disease","volume":"13","author":"Ferrara","year":"2008","journal-title":"CNS Spectrums."},{"key":"10.1016\/j.rcp.2017.05.010_bib0625","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1001\/archneur.65.12.1604","article-title":"Functional abnormalities underlying pathological gambling in Parkinson disease","volume":"65","author":"Cilia","year":"2008","journal-title":"Arch Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0630","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archneur.62.9.noc50009","article-title":"Pathological gambling caused by drugs used to treat Parkinson disease","volume":"62","author":"Dodd","year":"2005","journal-title":"Arch Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0635","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.21770","article-title":"Long-term follow-up of impulse control disorders in Parkinson's disease","volume":"23","author":"Mamikonyan","year":"2008","journal-title":"Mov Disord."},{"key":"10.1016\/j.rcp.2017.05.010_bib0640","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/mds.870130338","article-title":"Clozapine for dopaminergic-induced paraphilias in Parkinson's disease","volume":"13","author":"Fernandez","year":"1998","journal-title":"Mov Disord."},{"key":"10.1016\/j.rcp.2017.05.010_bib0645","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.parkreldis.2005.06.005","article-title":"Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy","volume":"11","author":"Klos","year":"2005","journal-title":"Parkinsonism Rel Disord."},{"key":"10.1016\/j.rcp.2017.05.010_bib0650","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1136\/jnnp.47.12.1283","article-title":"Increased rate of suicide among patients with Huntington's disease","volume":"47","author":"Schoenfeld","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.rcp.2017.05.010_bib0655","doi-asserted-by":"crossref","first-page":"191","DOI":"10.31887\/DCNS.2007.9.2\/arosenblatt","article-title":"Neuropsychiatry of Huntington's disease","volume":"9","author":"Rosenblatt","year":"2007","journal-title":"Dial Clin Neurosci."},{"key":"10.1016\/j.rcp.2017.05.010_bib0660","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.42.9.1791","article-title":"Paralimbic frontal lobe hypometabolism in depression associated with Huntington's disease","volume":"42","author":"Mayberg","year":"1992","journal-title":"Neurology."},{"key":"10.1016\/j.rcp.2017.05.010_bib0665","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/nmt.11.45","article-title":"Depression in the early stages of Huntington disease","volume":"1","author":"Epping","year":"2011","journal-title":"Neurodegener Dis Manag."},{"key":"10.1016\/j.rcp.2017.05.010_bib0670","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/YIC.0b013e3283348018","article-title":"Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR","volume":"25","author":"Holl","year":"2010","journal-title":"Int Clin Psychopharmacol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0675","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-0447.1994.tb01587.x","article-title":"Psychopathology in Huntington's disease patients","volume":"90","author":"Shiwach","year":"1994","journal-title":"Acta Psychiatr Scand."},{"key":"10.1016\/j.rcp.2017.05.010_bib0680","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1192\/apt.bp.107.005371","article-title":"Psychiatric and behavioural manifestations of Huntington's disease","volume":"16","author":"Jauhar","year":"2010","journal-title":"Adv Psychiatr Treat."},{"key":"10.1016\/j.rcp.2017.05.010_bib0685","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1176\/appi.ajp.158.5.799","article-title":"Cognitive correlates of obsessive and compulsive symptoms in Huntington's disease","volume":"158","author":"Anderson","year":"2001","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.rcp.2017.05.010_bib0690","first-page":"219","article-title":"Behavioral changes in Huntington Disease","volume":"14","author":"Craufurd","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0695","first-page":"644","article-title":"Obsessive-compulsive disorder symptoms in Huntington's disease: a case report","volume":"37","author":"Molano-Eslava","year":"2008","journal-title":"Rev Colomb Psiquiatr."},{"key":"10.1016\/j.rcp.2017.05.010_bib0700","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0006-3223(92)90049-6","article-title":"Obsessive-compulsive disorder in Huntington's disease","volume":"31","author":"Cummings","year":"1992","journal-title":"Biol Psychiatry."},{"key":"10.1016\/j.rcp.2017.05.010_bib0705","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0924-9338(01)00604-6","article-title":"Huntington's disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena","volume":"16","author":"Naarding","year":"2001","journal-title":"Eur Psychiatry."},{"key":"10.1016\/j.rcp.2017.05.010_bib0710","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-202625","article-title":"Psychosis with Huntington's disease: role of antipsychotic medications","author":"Ding","year":"2014","journal-title":"BMJ case reports."},{"key":"10.1016\/j.rcp.2017.05.010_bib0715","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1468-1331.2002.0354e.x","article-title":"Risperidone in chorea and psychosis of Huntington's disease","volume":"9","author":"Erdemoglu","year":"2002","journal-title":"Eur J Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0720","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1176\/appi.ajp.2008.08040503","article-title":"Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease","volume":"165","author":"Lin","year":"2008","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.rcp.2017.05.010_bib0725","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.psy.47.1.70","article-title":"Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease","volume":"47","author":"Alpay","year":"2006","journal-title":"Psychosomatics."},{"key":"10.1016\/j.rcp.2017.05.010_bib0730","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","article-title":"Cognitive impairment in Huntington disease: diagnosis and treatment","volume":"11","author":"Paulsen","year":"2011","journal-title":"Curr Neurol Neurosci Rep."},{"key":"10.1016\/j.rcp.2017.05.010_bib0735","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","article-title":"Effect of donepezil on motor and cognitive function in Huntington disease","volume":"67","author":"Cubo","year":"2006","journal-title":"Neurology."},{"key":"10.1016\/j.rcp.2017.05.010_bib0740","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5498\/wjp.v3.i3.62","article-title":"Acetylcholinesterase inhibitors in cognitive impairment in Huntington's disease: A brief review","volume":"3","author":"Vattakatuchery","year":"2013","journal-title":"World J Psychiatry."},{"key":"10.1016\/j.rcp.2017.05.010_bib0745","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0022-3999(02)00428-2","article-title":"Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update","volume":"53","author":"Tekin","year":"2002","journal-title":"J Psychosom Res."},{"key":"10.1016\/j.rcp.2017.05.010_bib0750","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s004150050541","article-title":"Depression in Parkinson's disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging","volume":"246","author":"Berg","year":"1999","journal-title":"J Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0755","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1176\/jnp.6.4.379","article-title":"The regional prefrontal syndromes: a theoretical and clinical overview","volume":"6","author":"Duffy","year":"1994","journal-title":"J Neuropsychiatry Clin Neurosci."},{"key":"10.1016\/j.rcp.2017.05.010_bib0760","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jns.2011.05.036","article-title":"Neuroanatomical correlates of depression and apathy in Parkinson's disease: magnetic resonance imaging studies","volume":"310","author":"Kostic","year":"2011","journal-title":"J Neurol Sci."},{"key":"10.1016\/j.rcp.2017.05.010_bib0765","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1001\/archneur.1993.00540080076020","article-title":"Frontal-subcortical circuits and human behavior","volume":"50","author":"Cummings","year":"1993","journal-title":"Arch Neurol."},{"key":"10.1016\/j.rcp.2017.05.010_bib0770","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology."}],"container-title":["Revista Colombiana de Psiquiatr\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034745017300665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034745017300665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T21:30:48Z","timestamp":1750368648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0034745017300665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":77,"alternative-id":["S0034745017300665"],"URL":"https:\/\/doi.org\/10.1016\/j.rcp.2017.05.010","relation":{},"ISSN":["0034-7450"],"issn-type":[{"type":"print","value":"0034-7450"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuropsiquiatr\u00eda de los trastornos del movimiento","name":"articletitle","label":"Article Title"},{"value":"Revista Colombiana de Psiquiatr\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcp.2017.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Asociaci\u00f3n Colombiana de Psiquiatr\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}